echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xinlitai HFpEF drug SAL007 clinical trial application accepted

    Xinlitai HFpEF drug SAL007 clinical trial application accepted

    • Last Update: 2022-05-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On April 19, Xinlitai announced that the clinical trial application of the drug recombinant human neuregulin 1-anti-HER3 antibody fusion protein injection (domestic project code: SAL007) has been accepted
    The application submitted by the company this time is a Phase I clinical trial application of SAL007 for the indication of HFpEF (heart failure with preserved ejection fraction) in chronic heart failure


    SAL007 (US project code: JK07, hereinafter referred to as "07") is an NRG-1 (neuregulin-1) fusion antibody drug independently developed by Salubris Bio in the United States and has global intellectual property rights.
    The intended indication is chronic heart failure


    This product is the company's first innovative biological drug that is reported in both China and the United States.
    It was approved for clinical trials by the US FDA in February 2020, and was approved for clinical trials by China's CDE in September 2020

    At present, SalubrisBio in the United States is enrolling the second dose group of the HFrEF (heart failure with reduced ejection fraction) phase I clinical trial, and it is expected to complete the enrollment in the near future; at the same time, it is preparing for the initiation of the HFpEF clinical trial

    A phase I clinical trial of HFrEF is underway in China


    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.